Condition category
Pregnancy and Childbirth
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status

Plain English Summary

Background and study aims
Pelvic organ prolapse is the bulging or drooping of any pelvic organs (bladder, uterus, bowel) into the vagina. Prolapse is a common gynaecologic condition caused by weakening of the supporting tissues of the pelvic floor. Prolapse operations may include vaginal hysterectomy (removal of the womb vaginally) or pelvic floor repair (tightening of the front or back wall of the vagina or support the top of vagina). Hormone (oestrogen) replacement might improve the condition of the vaginal wall and help strengthen the pelvic floor, reducing complications of surgery eg water infections and improving the quality of the surgical repair. Postmenopausal women with vaginal dryness are sometimes treated with oestrogen in the form of tablets (pessaries) they insert into the vagina. However, it's not known whether vaginal application of oestrogen might reduce complications during operations for prolapse and improve long term postoperative outcomes. The aim of the LOTUS study will be to test whether treatment with vaginal oestrogen pessaries, improves prolapse related quality of life after surgery. We also want to see whether surgical complications are reduced and sexual function improved in these patients. Before starting a large study, it's important to rehearse the trial plan in a small feasibility study (treatment v no treatment), to see, for example, how many eligible women could be recruited to the study, how many would be willing to have treatment assigned at random, and how many would stick with the treatment for a specified period of time. This feasibility study will also help calculate the number of patients required for a definitive study, and the resources needed.

Who can participate?
Postmenopausal women about to undergo surgery for a pelvic organ prolapse and that have not had HRT in the last 12 months.

What does the study involve?
Participants are randomly allocated into one of two groups. Those in group 1 (intervention) are put on a 6 week course of oestradiol (once daily for 2 weeks followed by twice weekly for four weeks) and then again twice weekly from 6-26 weeks after surgery. Those participants in group 2 (control) are not given the oestradiol treatment. All participants are then followed up 12 months after the surgery to assess their quality of life.

What are the possible benefits and risks of participating?
To date, there has been no robust data on the benefits of pre and postoperative oestrogen treatment in postmenopausal women undergoing POP surgery. A Cochrane review published in 2010 did not find any clear evidence to suggest whether oestrogens help in reducing the symptoms of POP.3 However due to frequent use, it was recommended that adequately powered RCTs with long term follow up is needed to identify benefits or risks.

Where is the study run from?
University of Birmingham Clinical Trials Unit (UK)

When is the study starting and how long is it expected to run for?
July 2015 to July 2017

Who is funding the study?
National Institute for Health Research (UK)

Who is the main contact?
Mrs Lisa Leighton

Trial website

Contact information



Primary contact

Mrs Lisa Leighton


Contact details

University of Birmingham
Birmingham Clinical Trials Unit
Division of Medical Sciences
Robert Aitken Institute
B15 2TT
United Kingdom

Additional identifiers

EudraCT number

2014-000179-18 number

Protocol/serial number


Study information

Scientific title

Local Oestrogen Treatment in postmenopausal women Undergoing pelvic organ prolapse Surgery (LOTUS) feasibility study



Study hypothesis

The aim of the LOTUS study is to establish whether treatment with vaginal oestrogen pessaries, for 6 weeks before and 52 weeks after prolapse repair surgery, improves prolapse related quality of life one year following surgery. We also want to assess whether surgical complications are reduced and sexual function improved. This will require a clinical trial of several hundred women, half of whom would receive oestrogen and half who would receive no treatment. This feasibility study is being conducted in order to help calculate the number required for a definitive study, and the resources needed.

Ethics approval

West Midlands Ethics Committee, 28/04/2015, ref: 15/WM/0092

Study design

Randomised; Interventional; Design type: Not specified, Treatment

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use contact details to request a participant information sheet


Topic: Reproductive health and childbirth; Subtopic: Reproductive Health and Childbirth (all Subtopics); Disease: Reproductive Health & Childbirth


Intervention group (Group A): This will comprise of 6 weeks course of oestradiol 10 µg preoperatively per vaginum (once daily for 2 weeks followed by twice weekly for four weeks) and then 10µg oestradiol per vaginum twice weekly from 6-26 weeks postoperatively
Follow Up Length: 12 month(s); Study Entry : Single Randomisation only

Intervention type



Drug names

Primary outcome measures

Improvement in prolapse related QoL at 12 months as assessed by PFDI SF20.

Secondary outcome measures

Improvement sexual function related quality of life (QoL) at 12 months with the use of PISQ 12
1. Reduction of intraoperative complications like tearing or button holing of the vagina and blood loss
2. Reduction in the incidence of surgical wound infection and urinary tract infection postoperatively
3. Validate Patient Global Impression of Improvement (PGI-I)19 in relation to the POP surgery, PFDI SF20 and PFIQ-7

Overall trial start date


Overall trial end date


Reason abandoned


Participant inclusion criteria

1. Postmenopausal women
2. Consented to undergo surgical intervention for pelvic organ prolapse
3. Have not received HRT in the last 12 months
4. Willing to be randomised
5. Give written informed consent; Target Gender: Female; Upper Age Limit 90 years ; Lower Age Limit 30 years

Participant type


Age group




Target number of participants

Planned Sample Size: 100; UK Sample Size: 100; Description: Postmenapausal women with pelvic organ prolapse (Obs & Gynae)

Participant exclusion criteria

1. Previous breast or uterine malignancy or other hormone dependent neoplasms
2. Genital bleeding of unknown origin
3. Previous thromboembolic episodes in relation to oestrogen therapy
4. Women who cannot understand speak or write in English
5. Women known to be allergic to any of the components of vaginal oestrogens
6. Two or more episodes of culture positive UTI in the last 6 months
7. Previous POP surgery
8. Voiding dysfunction(PVR>150ml)
9. Current or previous POP surgery involving mesh

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Birmingham Women’s Hospital (Lead site)
Mindelsohn Way
B15 2TG
United Kingdom

Trial participating centre

Croydon University Hospital
530 London Road Croydon
United Kingdom

Trial participating centre

Medway Maritime Hospital
Windmill Road
United Kingdom

Trial participating centre

Basingstoke and North Hampshire Hospital
Aldermaston Road Basingstoke
RG24 9NA
United Kingdom

Trial participating centre

Queen Alexandra Hospital
Southwick Hill Road Portsmouth
United Kingdom

Sponsor information


Birmingham & Black Country (University Hospital Birmingham NHS Foundation Trust)

Sponsor details

Research and Development
Queen Elizabeth Hospital
B15 2TH
United Kingdom

Sponsor type

Hospital/treatment centre



Funder type


Funder name

National Institute for Health Research

Alternative name(s)


Funding Body Type

government organisation

Funding Body Subtype

Federal/National Government


United Kingdom

Results and Publications

Publication and dissemination plan

This feasibility study is designed to identify if a substantive trial is possible, although the findings of this study may be of scientific interest to others in their own right. We plan the dissemination strategy in a number of ways: A report will be prepared for the funders and ethics committee. Findings will be more widely available via the trial study website. The feasibility findings will also be presented at local and national meetings such as the British Society of Urogynaecology or British Menopause Society. This will capture an extremely large audience of national and international clinicians. We will seek all opportunities to assess the willingness to participate throughout the feasibility study and gain research community support for in a substantive trial should such a RCT be proven feasible.

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes